• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Genetic Counselling & Testing

In most cases of ALS/MND (~90%), there is only one person in a family that has a diagnosis of ALS/MND; this is often referred to as “sporadic” ALS/MND. In a smaller proportion of cases (~10%), there are several individuals within the same family that have been diagnosed with ALS/MND; this is often referred to as “familial” ALS/MND. This raises suspicion for a genetic cause, as families share similar genes.

There are still cases of familial ALS/MND for which the underlying genetic cause is unknown. Similarly, absence of a family history in sporadic ALS/MND does not necessarily mean that there is no underlying genetic cause.

After an individual has been diagnosed with ALS/MND, they may inquire about genetic counselling and testing. All people living with ALS/MND should have access to, and be provided information on, genetic counselling and testing, regardless of whether they have sporadic or familial ALS/MND.

A consultation with a genetic counsellor will involve discussing the individual’s family medical history. The benefits and potential outcomes of genetic tests, and answers to any questions a person may have about the test or potential results, are also discussed. Moreover, a consultation with a genetic counsellor does not mean that a genetic test will be conducted. Instead, individuals use these consultations to decide if genetic testing is right for them.

The results of genetic tests in people with familial ALS/MND could identify a genetic mutation. Identifying a genetic mutation occurs in roughly 60 – 70% of people with familial ALS/MND.

Our understanding on how often ALS/MND associated mutations occur in people with sporadic ALS/MND is currently evolving, as genetic testing becomes more widely available.

A genetic counsellor or other healthcare providers can discuss options with the individual and their family if there is a positive test result.

To learn more about genetic testing and genetic counsellors, please refer to the resources provided below.

Infographics

The following are the Alliance’s infographics on the topic of Genetic Counselling and Testing.

The Alliance and Genetics
ALS/MND Genetically-Targeted Therapy Acceleration Timeline
Ethical Considerations in ALS/MND Genetics
Introduction to Genetics: What is genetic variation?
Introduction to Genetics: What is your genome?
ALS/MND Genetics: Why is genetics relevant to ALS/MND?
ALS/MND Genetics: Can genes affect the type of ALS/MND?
ALS/MND Genetics: What can we do about genetic ALS/MND? / Genética en la ELA/ENM: Qué podemos hacer nosotros sobre la genética en la ELA/ENM?

Resources

The following are resources from Members of the International Alliance of ALS/MND Associations on the topic of Genetic Counselling and Testing.

ETHICAL CONSIDERATIONS FOR GENETICS

A discussion of the risks and benefits of genetic testing in individuals who are symptomatic or have a family history of ALS. Different contexts and potential considerations for individuals who are symptomatic for ALS, with and without a family history of ALS, or those who are asymptomatic for ALS but considering undergoing genetic testing will be discussed


GENETICS – COUNSELLING & TESTING

The Alliance´s Fundamental Rights were updated in 2021 to include the right to have access upon diagnosis to genetic counselling and testing. There are numerous therapies in development for the genetic forms of ALS/MND. For people living with ALS/MND to be able to access clinical trials, and future potentially approved therapies, access to both genetic counselling and testing will be necessary. This webinar touched on; what is genetic counselling and role of a genetic counsellor, what is involved in genetics counselling & testing, availability, awareness of ethical issues surrounding genetic testing , psychological effects of genetic testing and tackling difficult concepts in ALS/MND clinical genetics.


Introduction to ALS/MND Genetics

Recent discoveries are adding significant knowledge to the understanding of genetics in ALS/MND and potential treatments. This webinar provided an overview of the current ALS/MND landscape and an understanding of genetics, so that people impacted by ALS/MND and their families have the basic tools to understand what this means and their options.

 

 

Inherited MND: Introduction

This guide provides an introduction to understanding inherited ALS/MND. It was created by the MND Association (MNDA) as part one of a three guide series. Part one discusses what to consider, such as genetic testing and finding care and support when undergoing these types of consultations.

https://www.mndassociation.org/app/uploads/2019/02/B1-Introduction-to-inherited-MND.pdf

Language: English
Subject Areas: Genetic Testing, Genetic Counselling, For People with ALS/MND, For Caregivers

Genetic Testing for ALS: Fact Sheet

This short fact sheet provides people living with ALS/MND and caregivers information about genetic testing. This includes a description of how genes may play a role in ALS/MND, what the tests look for, and what a positive test means.

https://www.als.ca/wp-content/uploads/2017/04/ALSCAN-GeneticTesting-EN.pdf

Language: English
Subject Areas: Genetic Testing, For People with ALS/MND, For Caregivers

Genetic Testing For ALS

This resource is provided by the ALS Association (ALSA) for people living with ALS/MND. Information about genetic counselling and its benefits are provided. Additionally, this resource supplies information on how genetic testing works and the pros and cons of genetic testing for people living with ALS/MND and their caregivers or family members.

https://www.als.org/understanding-als/who-gets-als/genetic-testing

Language: English
Subject Areas: Genetic Testing, Genetic Counselling, For People with ALS/MND, For Caregivers

Familial ALS

ALSA created this booklet as a resource for people living with ALS/MND and caregivers to learn more about the science behind genetic testing and when a person may want to receive genetic testing. In addition, this booklet discusses the positive and negative implications that a person may need to consider before genetic testing.

https://www.als.org/sites/default/files/2020-04/Familial-ALS-Booklet-DIGITAL-04-17-18.pdf

Language: English
Subject Areas: Genetic Testing, Genetic Counselling, For People with ALS/MND, For Caregivers

About Genetic Counselors

This website is often referred to by ALSA for individuals to learn more about genetic counselling and how they can be a part of your multidisciplinary healthcare team. Although based in the United States, this resource provides foundational information that may benefit individuals living with ALS/MND globally.

https://www.nsgc.org/About/About-Genetic-Counselors

Language: English
Subject Areas: Genetic Counselling, Multidisciplinary Healthcare Team, For People with ALS/MND, For Caregivers

Primary Sidebar

Care services

  • Genetic Counselling & Testing
  • Mental Health Support
  • Nursing and Symptom Management
  • Nutrition and Swallowing
  • Occupational Therapy and Activities of Daily Living
  • Physiotherapy and Mobility
  • Respiratory Care
  • Speech Therapy and Communication
  • Support for Family & Caregivers
  • Technology

  • Bayley, Australia

    Bayley, Australia

  • Natalya Rybakova, Russian Charity ALS Foundation

    Natalya Rybakova, Russian Charity ALS Foundation

  • Roy

    Roy
    roy

  • Bob Simonds and Drew O'Neil, USA

    Bob Simonds and Drew O’Neil, USA

  • Philip Brindle,  MND Association,  Diagnosed 2015,  England

    Philip Brindle, MND Association, Diagnosed 2015, England

  • Hanne Stenmose, Muskelsvindfonden, Denmark

    Hanne Stenmose, Muskelsvindfonden, Denmark

  • Angie Bordaen, Diagnosed 2014,  ALS Liga België, Belgium

    Angie Bordaen, Diagnosed 2014, ALS Liga België, Belgium

  • Bjarne Hytjanstorp, ALS Norge, Norway

    Bjarne Hytjanstorp, ALS Norge, Norway

  • Mauril Belanger

    Mauril Belanger

  • Brigitte Wernli,  Association ALS Switzerland,  Diagnosed 2014

    Brigitte Wernli, Association ALS Switzerland, Diagnosed 2014

  • Dick Dayton, USA

    Dick Dayton, USA

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Mike Small, Motor Neurone Disease (MND) Association, UK

    Mike Small, Motor Neurone Disease (MND) Association, UK

  • Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

  • Wilfried Leusing, Diagnosed 2010 , DGM, Germany

    Wilfried Leusing, Diagnosed 2010 , DGM, Germany

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Margarita Pizarro, Asociacion ELA Argentina, Diagnosed 2017, Argentina

    Margarita Pizarro, Asociacion ELA Argentina, Diagnosed 2017, Argentina

  • Tammy Moore and Eddy Lefrancois

    Tammy Moore and Eddy Lefrancois

  • Nicholas (Nic) Bowman, MND Association of South Africa,  Diagnosed 2016,  Australia

    Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

  • Yolanda Armendariz, Diagnosed 2017 , FYADENMAC, Mexico

    Yolanda Armendariz, Diagnosed 2017 , FYADENMAC, Mexico

  • Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

    Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

  • Mark Miller

    Mark Miller

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Norm MacIsaac,  ALS Society of Canada,  ALS Society of Quebec,  Diagnosed 2014

    Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014

  • Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

    Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

  • Ian Gale, MND Australia

    Ian Gale, MND Australia

  • Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

    Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Shera Mukherjee, Diagnosed 2013,  Asha Ek Hope Foundation, India

    Shera Mukherjee, Diagnosed 2013, Asha Ek Hope Foundation, India

  • Liong Ting Ngu, MND Malaysia, Diagnosed 2014

    Liong Ting Ngu, MND Malaysia, Diagnosed 2014

  • JP

    JP

  • Bob Simonds and Drew O'Neill , Les Turner ALS Foundation, USA

    Bob Simonds and Drew O’Neill , Les Turner ALS Foundation, USA

  • Mike Rannie,  ALS Canada,  Diagnosed 2017

    Mike Rannie, ALS Canada, Diagnosed 2017

  • Yessenia Hernandez Mendoza, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Yessenia Hernandez Mendoza, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Wilfried Leusing

    Wilfried Leusing

  • Jon Newsome, USA

    Jon Newsome, USA

  • Zelina Brito, Diagnosed 2018, Brazil

    Zelina Brito, Diagnosed 2018, Brazil

  • Anthony (Tony) Lynch, MND New South Wales, Diagnosed 2016, Australia

    Anthony (Tony) Lynch, MND New South Wales, Diagnosed 2016, Australia

  • Shay Rishoni, Diagnosed 2011 - Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 – Prize4Life, Israel

  • Ana Lilia RodriguezApoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Ana Lilia RodriguezApoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Karl Hughes, Diagnosed 2010 , IMNDA,  Ireland

    Karl Hughes, Diagnosed 2010 , IMNDA, Ireland

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Jorge Melo, ABrELA, Brazil

    Jorge Melo, ABrELA, Brazil

  • Ann Nicol

    Ann Nicol

  • Willi Klein

    Willi Klein

  • Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • March of Faces Photo Submission_ALEX_ELA ARGENTINA

    March of Faces Photo Submission_ALEX_ELA ARGENTINA

  • Debbie Craghill, USA

    Debbie Craghill, USA

  • Irene McCaughey, Diagnosed 2011,  MND Australia

    Irene McCaughey, Diagnosed 2011, MND Australia

  • Sébastien Batiot, Diagnosed 2012 , ARSLA, France

    Sébastien Batiot, Diagnosed 2012 , ARSLA, France

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login